baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CENCORA INC/ US03073E1055 /

2024-07-24 5:32:16 PM	Chg. -1.30	Volume	Bid5:32:16 PM	Ask5:32:16 PM	Market Capitalization	Dividend Y.	P/E Ratio
205.75EUR	-0.63%	0 Turnover: -	-Bid Size: -	-Ask Size: -	41.53 bill.EUR	-	-

GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 05-28 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...

GlobeNewswire 05-15 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...

GlobeNewswire 05-13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...

GlobeNewswire 05-09 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...

GlobeNewswire 05-02 Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire 04-29 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...

GlobeNewswire 04-17 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners

GlobeNewswire 04-15 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

GlobeNewswire 03-22 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...

GlobeNewswire 03-18 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

GlobeNewswire 03-18 Parexel Announces CEO Succession Plan

GlobeNewswire 03-12 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

GlobeNewswire 02-14 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...

GlobeNewswire 01-23 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...

GlobeNewswire 01-02 Coherus Announces U.S. Launch of LOQTORZI™

GlobeNewswire 2023-12-22 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...

GlobeNewswire 2023-12-19 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...

GlobeNewswire 2023-12-06 Outlook Therapeutics® Announces Strategic Organizational Realignment

GlobeNewswire 2023-11-27 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...

GlobeNewswire 2023-11-14 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...

GlobeNewswire 2023-11-02 Outlook Therapeutics® Provides Update on Type A Meetings with FDA

GlobeNewswire 2023-11-01 Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...

Newsfile Corp 2023-10-26 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694

GlobeNewswire 2023-09-29 Outlook Therapeutics® Requests Type A Meeting With FDA

CENCORA INC/ US03073E1055 /

If you wish to receive reply to your feedback, please provide your email address.